Get a free sample of Phenylketonuria (PKU) Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Phenylketonuria (PKU) Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Phenylketonuria Treatment Market Size
Phenylketonuria Treatment Market size was valued at USD 737.7 million in 2023 and is estimated to grow at a CAGR of 7.2% from 2024 to 2032. The increasing demand for PKU treatment is driven by several factors including the rising incidence of PKU globally and advancements in treatment options.
Enhanced newborn screening programs are leading to earlier detection and diagnosis, which boosts the demand for effective management therapies. Also, ongoing research and development are yielding new therapeutic solutions such as gene therapy and novel drug formulations which tend to improve patient outcomes. For instance, in November 2023, new research from the Perelman School of Medicine at the University of Pennsylvania explores potential future treatments using advanced CRISPR gene editing techniques, specifically prime and base editing. These advancements expect to pave the way for innovative therapies in genetic medicine. Furthermore, increased awareness among healthcare providers and patients about the benefits of early and continuous treatment contributes to the growing market demand for PKU treatments.
PKU treatment refers to medical interventions and therapies aimed at managing and mitigating the effects of PKU, a genetic disorder characterized by the body's inability to metabolize the amino acid phenylalanine. The primary goal of PKU treatment is to reduce phenylalanine levels in the blood to prevent neurological damage and other complications.
What is the size of the phenylketonuria treatment market?
The phenylketonuria treatment industry was valued at USD 737.7 million in 2023 and is anticipated to register a 7.2% CAGR between 2024 and 2032 augmented by the rising incidence of PKU globally and advancements in treatment options.
Why is the demand for classic PKU treatment spurring?
The classic PKU segment will showcase a 7% CAGR over 2024-2032, because of its high prevalence and the well-established need for lifelong management.
What is the value of the U.S. phenylketonuria treatment market?
The U.S. PKU treatment market size is anticipated to reach USD 502.5 million by 2032, thrusted by advancements in diagnostic and treatment technologies.
Who are the major phenylketonuria treatment industry players?
Abbott Laboratories, American Gene Technologies, APR Applied Pharma Research s.a., BioMarin Pharmaceutical Inc., and Codexis, Inc., among others.